The BE COMPLETE study, a multicenter, double-blind, placebo-controlled, randomized phase III trial, assesses the efficacy of bimekizumab in patients with active psoriatic arthritis who previously experienced inadequate responses or intolerance to anti-TNF therapy. Here, TNF is linked to psoriatic arthritis.